Mainstay Medical secured $108m to support the US launch of its ReActiv8 device for treating back pain, along with continued commercialization of the device in Europe and Australia.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?